Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival

Yohann Dabi1, Cyrille Huchon2, Lobna Ouldamer3, Sofiane Bendifallah4, Pierre Collinet5, Alexandre Bricou6, Emile Daraï4, Marcos Ballester4, Vincent Lavoué7, Bassam Haddad1, Cyril Touboul1,4,8* and For the Groupe de Recherche FRANCOGYN

Abstract
Background: The most appropriate management for patients with stage IV ovarian cancer remains unclear. Our objective was to understand the main determinants associated with survival and to discuss best surgical management.

Methods: Data of 1038 patients with confirmed ovarian cancer treated between 1996 and 2016 were extracted from maintained databases of 7 French referral gynecologic oncology institutions. Patients with stage IV diseases were selected for further analysis. The Kaplan–Meier method was used to estimate the survival distribution. A Cox proportional hazards model including all the parameters statistically significant in univariable analysis, was used to account for the influence of multiple variables.

Results: Two hundred and eight patients met our inclusion criteria: 65 (31.3%) never underwent debulking surgery, 52 (25%) underwent primary debulking surgery (PDS) and 91 (43.8%) neoadjuvant chemotherapy and interval debulking surgery (NACT–IDS). Patients not operated had a significantly worse overall survival than patients that underwent PDS or NACT–IDS (p < 0.001). In multivariable analysis, three factors were independent predictors of survival: upfront surgery (HR 0.32 95% CI 0.14–0.71, p = 0.005), postoperative residual disease = 0 (HR 0.37 95% CI 0.18–0.75, p = 0.006) and association of Carboplatin and Paclitaxel regimen (HR 0.45 95% CI 0.25–0.80, p = 0.007).

Conclusions: Presence of distant metastases should not refrain surgeons from performing radical procedures, whenever the patient is able to tolerate. Maximal surgical efforts should be done to minimize residual disease as it is the main determinant of survival.

Keywords: Ovarian cancer, Stage IV, Debulking surgery, Chemotherapy, Prognostic factors, Post-operative residual disease

Background
Ovarian cancer remains the leading cause of death from gynecological cancer in developed countries [1]. The lack of effective screening results in a majority of patients diagnosed with advanced stage diseases and around 20% of the newly diagnosed patients have a stage IV disease [2]. Standard of care for patients with epithelial ovarian carcinoma (EOC) include the combination of a cytoreductive surgery to achieve no residual disease and a platinum–based chemotherapy regimen [3, 4].

The most important and independent prognostic factor identified in EOC is the amount of residual disease following cytoreductive surgery. The largest the residual...
tumor, the worst the prognosis is [3, 5, 6]. To minimize residual disease following surgery, radical and even ultra–radical surgery must be performed sometimes. Radical surgery comprising, in addition to the hysterectomy and bilateral adnexectomy, total omentectomy and appendectomy +/- pelvic and para aortic lymphadenectomy, en bloc removal of the uterus, both ovaries, the pelvic peritoneum and recto-sigmoid with or without simple peritoneectomies. Ultra–radical surgery, that is, a radical procedure plus at least one of the following: extensive peritoneectomies including partial resection of the diaphragm or resection of subcapsular liver metastases, cholecystectomy, or splenectomy, resection of that tail of the pancreas and/or other bowel resection, partial gastrectomy, etc. [7]. The surgery is all the more aggressive that the disease is extensive and by definition, patients with stage IV disease have the most extensive disease [8, 9].

The cost to achieve a complete resection is a high perioperative morbidity and mortality. Indeed, complications in as high as 50% of cases have been reported when treating patients with EOC by radical surgery [10, 11]. Patients not eligible to primary cytoreductive surgery undergo neoadjuvant chemotherapy followed by interval debulking surgery. While neoadjuvant chemotherapy did reduce surgical complexity and increased the number of patients with complete resection, it is at best non inferior to upfront surgery for survival [4, 12, 13]. Unfortunately, there is only few data regarding specifically patients with stage IV disease [14–16] as many reports usually pool analysis with patients staged IIIIC. These patients have the most extensive intra-abdominal disease associated with distant metastases and complete removal of disease requires radical procedures and possibly extra-abdominal surgery. Such procedures are highly morbid and could delay important adjuvant chemotherapy [17, 18]. Should these patients undergo highly morbid radical/ultra–radical procedures if surgery does not better than chemotherapy only? Is postoperative residual disease also an important prognostic factor in this specific subgroup of patients? Few authors addressed the question of their management and it remains unclear whether they do benefit from any surgery at all and if yes, if the most appropriate management is primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery [19–21]. Eventually, the understanding of the determinants of survival in this population is poor.

Our study therefore focused on understanding the main predictors of survival in patients with stage IV EOC. Our secondary objective was to discuss the most appropriate management in this specific population with extensive peritoneal disease and distant metastases.

**Methods**

We conducted a retrospective study using maintained databases from 7 French referral gynecologic oncology institutions (University departments of gynecology of Creteil, Tenon, Poissy, Lille, Tours, Bondy and Rennes Hospitals). These databases registered all patients diagnosed with ovarian cancer at any stage between January 1996 and December 2016. The research protocol was approved by the Institutional Review Board (IRB) of the French College of Obstetrics and Gynecology (CEROG 2016-GYN-1003).

Patients with stage IV EOC were then selected for further analysis. As the International Federation of Gynecology and Obstetrics (FIGO) classification for EOC changed over the years, all patients’ stages were reassessed using the latest version of the classification and stage IV was defined as the presence of any distant metastasis, including inguinal lymph node metastasis and pleural effusion [22]. Patients with pleural effusion had a cytology by fine needle aspiration to confirm the presence of malignant cells (stage IVA). Exclusion criteria were: (i) Patients with non-epithelial tumors; (ii) Patients with undetermined FIGO stage; (iii) Patients with numerous missing data; (iv) Patients that underwent explorative and/or cytoreductive surgery elsewhere.

Furthermore, we excluded from analysis patients never operated because of poor general condition as well as those that refused surgical management. All patients underwent clinical examination. Performance status was evaluated at the time of initial management to evaluate whether the patient could bear surgery and/or chemotherapy. Patients presenting with old age were assessed by the oncogeriatric.

Preoperative workup included at least an abdominal–pelvic computed tomography scan (CT–scan) and most patients had a blood test to assess Carbohydrate Antigen 125 (CA125) level. Each patient’s case was systematically reviewed by a multidisciplinary board that included at least a certified an oncologist, a pathologist, a radiologist and an experimented surgeon. All surgeries were performed by a qualified gynecologic oncologist, trained to digestive resections and to supra—mesocolic surgery. Initial management consisted in an explorative laparoscopy to determine the extent of the peritoneal spread and the resectability of the disease. Decision to proceed to either primary debulking surgery (PDS) or neoadjuvant chemotherapy then interval debulking surgery (NACT—IDS) was then decided based on the resectability, if the patient could bear it as recommended. Cytoreductive surgeries were always performed with intend to achieve no residual disease. It included at least a midline laparotomy, total hysterectomy, bilateral salpingo—oophorectomy and infragastric omentectomy. A more extensive surgery was
performed when indicated and could involve digestive tract resections, upper abdominal resections (UAR) such as diaphragmatic resection, splenectomy, lymph nodes dissections, hepatectomy, and any other gesture to obtain no residual disease. Surgical complexity was assessed using the complexity score described by Aletti et al. [23].

All patients received chemotherapy regimens that were platinum based. Chemotherapy was started usually between 4 and 6 weeks following surgery but in cases of postoperative complications, this delay could be longer (until 2 month). Patients not fitting for PDS were surgically reevaluated after 2 to 4 cycles of NACT, depending on the centers. Patients non resectable following 6 cycles of NACT were considered never resectable and were treated with chemotherapy alone, if they could tolerate it. Second line chemotherapy for patients that progressed during NACT was decided with the referent oncologist.

Post-operative residual disease (RD) after PDS or IDS were classified as defined by Chang and Bristow [24]: no RD when all disease was removed, optimal when the largest tumor left was between 0.1 and 1 cm² and gross RD when it was > 1 cm².

Postoperative management
All patients had a post-operative visit at 1 month. Postoperative complications were classified using the validated Clavien—Dindo scale [25]. Severe post-operative complications were those graded ≥ 3. Regular follow up consisted in clinical examination and blood testing including CA 125 dosage. Abdominal pelvic CT–scan was performed either if there was a clinical suspicion of recurrence or at least every 4 months for 2 years and every 6 months after. Disease recurrence was diagnosed on biopsy or imaging exam. Date of initial explorative surgery was used to calculate Overall Survival (OS) as well as the Progression Free Survival (PFS).

Statistical analysis
Databases were managed using Excel (Microsoft Corporation, Redmond, WA, USA) and statistical analyses were performed using R software (3.3.1 version, available online). Statistical analysis was based on the Student’s t test for continuous variable and the χ² test or Fisher’s exact test for categorical variables. The Kaplan–Meier method was used to estimate the survival distribution. Comparisons of survival were made using the log rank test. A Cox proportional hazards model including all the parameters statistically significant in univariate analysis, was used to account for the influence of multiple variables. Values of p < 0.05 were considered to denote significant differences (Additional file 1: Fig. 1).

Results
Main characteristics of the patients included
Between 1996 and 2016, 1038 patients were treated for an ovarian cancer within our institutions. Of these, 208 met our inclusion criteria: 65 had chemotherapy alone, 52 underwent PDS and 91 NACT-IDS (Fig. 1).

Sixteen patients (7.7%) with stage IV disease were of poor general condition following chemotherapy not suitable for surgery and 4 patients refused surgical management. The other patients treated with chemotherapy alone were so because of disease progression during chemotherapy.

The main characteristics of the patients included are displayed in Table 1. Patients treated solely with chemotherapy were significantly older than the others (p = 0.009). Patients treated with up–front surgery had significantly less often serous histological subtype (p < 0.001) and lower CA125 level (p = 0.04). Patterns of metastases locations were similar between the groups except for a lower rate of pleural effusion within patients treated with up–front surgery (p = 0.03).

The complexity of the surgery was higher for the patients treated with PDS when compared to those treated with NACT IDS (23/52, 44.2% vs 24/91, 26.4% for highly complex procedures, p = 0.01). There were a significantly higher proportion of patients with no RD in the group treated by PDS (40/52 76.9% vs 49/91, 53.8%, p = 0.01) (Table 2). The intraoperative complications in the group of patients treated with primary debulking surgery were as follow: 1 nervous lesion, 1 urinary, 3 hemorrhages, 1 pneumothorax. The complications in the group of patients treated with neoadjuvant chemotherapy and interval debulking surgery were as follow: 5 vascular lesions (hemorrhages), 7 pneumothorax, 1 digestive.

Twenty-five (48.1%) and 28 (30.8%) patients experienced post-operative complications in the PDS and NACT–IDS groups, respectively. The complications in the group of patients treated with primary debulking surgery were as follow: 5 infections, 6 embolism, 4 respiratory, 8 digestive, 2 bleeding. The complications in the group of patients treated with neoadjuvant chemotherapy and interval debulking surgery were as follow: 5 infections, 7 respiratory, 6 digestive, 4 bleeding, 3 lymphocele, 3 others.

There was a trend toward more complications in patients treated with PDS without reaching statistical significantly (p = 0.06). None of the patients operated died within 30 days (immediate post–operative death).
Survival analysis
Median follow up was of 19.5 months (min: 0.2 max: 130.6).

Patients treated solely with chemotherapy had a significantly worse progression free survival (p < 0.001) and overall survival than patients that underwent PDS or NACT–IDS (p < 0.001) (Fig. 2 and Additional file 1: Fig. 1). Patients treated with up front surgery had longer progression free and overall survival than those treated with NACT–IDS (p < 0.001 and p = 0.03, respectively).

Kaplan–Meier curves for overall survival in patients operated stratified by post-operative RD are presented in Fig. 3. Patients with no RD following surgery (PDS or NACT–IDS) and those with non–null postoperative RD had similar PFS but the latest had worse overall survival (p < 0.01).

Cox model on factor influencing overall survival
In univariate analysis, an age > 65 years at the time of diagnostic (p < 0.001), the surgery act (upfront surgery or after neoadjuvant chemotherapy) (p < 0.001), post-operative residual disease (p < 0.001), a platinum and taxol based chemotherapy (p < 0.001) and the presence of intra-abdominal organ metastases (p = 0.0209) were all significantly associated with overall survival (Table 3).

In multivariable analysis, three factors were independent predictors of survival: upfront surgery (HR 0.32 95% CI 0.14–0.71, p = 0.005), post-operative residual disease = 0 (HR 0.37 95% CI 0.18–0.75, p = 0.006) and association of Carboplatin and Paclitaxel regimen (HR 0.45 95% CI 0.25–0.80, p = 0.007). The other parameters were not independent predictors of survival in our cohort (Table 3).

Discussion
We found patients diagnosed with stage IV ovarian cancer had benefit from debulking surgery with improved PFS and OS when compared to non-operated patients.

Debulking strategy in ovarian cancer results from more than 40 years of surgical evolution and understanding of the disease. Postoperative residual disease is, to date, the best predictor of survival in patients with advanced disease [3, 5, 6]. However, the literature is unclear regarding the benefit patients with distant organ metastases could harvest from debulking surgery to complete resection of the disease and if they do, which of them are and how to select them. Some authors defend the idea stage IV of the disease should be considered as a distinct
Table 1  Main characteristics of the patients included

|                          | Chemotherapy only N = 65 | Primary debulking Surgery N = 52 | Interval debulking surgery N = 91 | p-value |
|--------------------------|--------------------------|----------------------------------|----------------------------------|---------|
| Age (years)              | 68.4 (57–78)             | 56.6 (47.8–67.25)                | 58.8 (51–66.5)                   | <0.001  |
| BMI                      | 25.0 (21.0–27.5)         | 26.7 (22.1–29.7)                 | 24.6 (20.4–26.4)                 | 0.16    |
| Histology                |                          |                                  |                                  |         |
| Serous                   | 57 (87.7)                | 30 (57.7)                        | 73 (80.2)                        | <0.001  |
| Mucinous                 | 1 (1.5)                  | 2 (3.8)                          | 1 (1.1)                          |         |
| Endometrioid             | 0                       | 4 (7.7)                          | 9 (9.9)                          |         |
| Transitional cell        | 0                       | 1 (1.9)                          | 0                                |         |
| Clear cell               | 1 (1.5)                  | 4 (7.7)                          | 0                                |         |
| Mixed                    | 0                       | 6 (11.5)                         | 5 (5.5)                          |         |
| Other                    | 3 (4.6)                  | 3 (5.8)                          | 2 (2.2)                          |         |
| Unknown                  | 3 (4.6)                  | 2 (3.8)                          | 1 (1.1)                          |         |
| Metastasis site          |                          |                                  |                                  |         |
| Intrahepatic             | 22 (33.8)                | 14 (26.9)                        | 20 (22.0)                        | 0.25    |
| Intra abdominal organ metastasesa | 11 (16.9)             | 16 (30.8)                        | 15 (16.5)                        | 0.3     |
| Pleural effusion         | 23 (35.4)                | 9 (17.3)                         | 41 (45.1)                        | 0.003   |
| Pleural metastasis       | 8 (12.3)                 | 3 (5.8)                          | 11 (12.1)                        | 0.42    |
| Over diaphragmatic metastases | 16 (24.6)             | 12 (23.1)                        | 24 (26.4)                        | 0.9     |
| Unknown                  | 16 (24.6)                | 0                                | 0                                |         |
| CA125 level at diagnosis | 4450 (378–2275)          | 1451 (227–1553)                  | 2499 (530–3193)                  | 0.04    |
| Initial chemotherapy     |                          |                                  |                                  |         |
| Received platinum        | 44 (67.7)                | 47 (90.4)                        | 78 (85.7)                        | 0.002   |
| Received taxane          | 40 (61.5)                | 40 (76.9)                        | 73 (80.2)                        | 0.03    |

Data are given as mean (interquartile range) or n (%)

a  Intra abdominal organs metastases: pancreas, spleen, digestive mucosa

Table 2  Surgery outcomes in patients with stage IV ovarian cancer

|                                | Primary debulking surgery N = 52 | Neo-adjuvant chemotherapy–interval debulking surgery N = 91 | p-value |
|--------------------------------|----------------------------------|------------------------------------------------------------|---------|
| Bowel resection                | 24 (46.1)                        | 29 (31.9)                                                  | 0.12    |
| Upper abdominal surgical proceduresa | 30 (57.7)             | 37 (40.7)                                                  | 0.07    |
| Complexity of the surgery     |                                  |                                                            | 0.01    |
| Low                            | 15 (28.8)                        | 19 (20.9)                                                  |         |
| Intermediate                   | 14 (26.9)                        | 48 (52.7)                                                  |         |
| High                           | 23 (44.2)                        | 24 (26.4)                                                  |         |
| Intraoperative complication    | 6 (11.5)                         | 13 (14.3)                                                  | 0.83    |
| Postoperative residue          |                                  |                                                            |         |
| Optimal cytoreduction RD < 1 cmb | 3 (5.8)                          | 2 (2.2)                                                    | 0.3     |
| Complete resection: no RD     | 40 (76.9)                        | 49 (53.8)                                                  | 0.01    |
| Postoperative complications   | 25 (48.1)                        | 28 (30.8)                                                  | 0.06    |

Data are given as n (%)

a  Upper abdominal surgical procedures = splenectomy, gallbladder resection, liver resection, diaphragmatic resection

b  Largest residual tumor nodule measuring 1 cm or less
We feel the conclusions of the studies that included a majority of stage IIIC patients should not be extrapolated to patients with stage IV. The major result of our study is the predominance of intra-peritoneal disease on overall survival, despite significant rate of distant organ metastasis.

Perri et al. showed isolated thoracic recurrences, without concomitant abdominal recurrence, are anecdotic [26]. This highlights the importance of abdominal control of the disease in these patients. Patients treated with chemotherapy alone had worse prognostic than those operated, despite important complications rates (48.1% and 30.8% in patients operated that undergone PDS and NACT–IDS, respectively) and frequent upper abdominal procedures. As we were not able to report performances status in our cohort, it remains possible patients never operated were in worse condition prior to any treatment, with more comorbidities and more aggressive diseases, which could bias our results. However, only a

### Table 3 Cox models

| Variables                              | Univariable analysis | Multivariable analysis |
|----------------------------------------|----------------------|------------------------|
|                                        | HR (95% CI)          | p-value                | HR (95% CI)           | p-value  |
| Age > 65 years                         | 2.4 (1.6–3.6)        | < 0.001                |                       |          |
| Surgical complexity                    |                      | 0.104                  |                       |          |
| Low                                    | Ref                  |                       |                       |          |
| Intermediate                           | 1.2 (0.7–2.3)        |                       |                       |          |
| High                                   | 0.5 (0.3–1.0)        |                       |                       |          |
| CA 125 > 500                           | 1.0 (0.6–1.6)        | 0.96                   |                       |          |
| Chemotherapy only                      | Ref                  | < 0.001                |                       |          |
| NACT–IDS                               | 0.2 (0.1–0.3)        | 0.48 (0.22–1.01)       | 0.054                 |          |
| PDS                                    | 0.1 (0.1–0.2)        | 0.32 (0.14–0.71)       | 0.005                 |          |
| Postoperative residual disease > 0    | Ref                  | < 0.001                |                       |          |
| Postoperative residual disease = 0 (complete surgery) | 0.2 (0.20–0.21) | 0.37 (0.18–0.75) | 0.006 |
| Association of Carboplatin and Paclitaxel | 0.4 (0.2–0.56)  | < 0.001                | 0.45 (0.25–0.80)      | 0.007 |

#### Univariable and multivariable analysis of the factors influencing overall survival in patients with stage IV epithelial ovarian cancer

**Fig. 2** Kaplan Meier curve for overall survival stratified by initial management. In red dashed line: patients with surgical staging. In black: Patients treated with chemotherapy only; In Red: patients treated by NACT–IDS; In blue: patients treated by PDS. Patients not operated had a significantly worse prognostic than patients operated (p < 0.001)
limited number of patients were treated with chemotherapy alone because of poor general condition following chemotherapy. Furthermore, we found patients operated had not only improved overall survival but also progression free survival. Response to chemotherapy could be an interesting parameter to help clinicians selecting the patients that will benefit from radical/ultra–radical surgery [27].

We found primary debulking surgery was an independent predictor of survival. New studies keep fueling the debate between upfront surgery and neoadjuvant chemotherapy. Usually, neoadjuvant chemotherapy is preferred for patients with initially non–resectable disease. Makar et al. in their recent review of the literature concluded stage IV disease was not a contraindication to PDS but neoadjuvant chemotherapy is preferable in cases of multiple intrahepatic/lung metastases or with massive ascites with miliary spread [28]. The management of the patients in our series was in accordance with makar et al. conclusions, explaining why the populations weren’t totally comparable. A limitation of our work is that data regarding the peritoneal cancer index (PCI) is missing. Some upper abdominal areas disease are known to predict poor oncological outcomes [29]. Furthermore, the better survival in patients treated with upfront surgery could reflect a lower disease burden initially. Eventually, The fact that the surgical complexity was not associated with survival suggests that extended surgeries could have overtook the bad prognosis of extended intra-peritoneal diseases. This paradigm was also raised by other authors [30].

Postoperative residual disease was a strong independent predictor of survival in our cohort, which justifies surgical effort to achieve no abdominal residual disease. Other studies suggested this factor could be important, as summarized by Ataseven et al. in their recent review [31]. The fact that none of the metastases locations was associated with survival, along with the impact of residual disease following surgery, underline the prognosis of these patients is driven by the evolution of the abdominal disease. One limit of our study is that precise location of the metastases is not available, which could possibly impact survival. However, our results are in line with those reported by Winter et al. [32] showing better survival when complete surgery is achieved, despite a distant metastasis rate of 12.5% and hepatic metastasis of 17.8%. In their 360 patients’ cohort, survival significantly decreased from 5 cm² of residual disease. It is of note that even those with postoperative residual disease between 0.1 and 5 cm benefited from the surgery. In our cohort, none of the patients had extra abdominal procedures performed before or during the cytoreductive surgery. Most of the literature focused on thoracic procedures, whose safety has been proven but not their impact on prognostic [33]. Bristow et al. reported increased survival in patients with intrahepatic metastases undergoing complete disease removal, both abdominal and hepatic [16].

The use of a combined platinum and taxane based chemotherapy regimen had an independent positive impact on overall survival in our cohort, further confirming the results reported by Atavensen et al. [31]. The importance of the chemotherapy is enhanced by the presence of extra–abdominal disease that cannot be cured otherwise. In the cohort of Winter, the patients had chemotherapy based on Cisplatin and Paclitaxel, which is not the standard regimen anymore since the

![Fig. 3](image-url)  
**Fig. 3** Kaplan Meier curve for overall survival in patients operated stratified by postoperative residual disease. In black: Patients with chemotherapy only; In blue and green: patients treated by PDS with no residual disease and with macroscopic residual disease, respectively; In red and purple: patients treated by PDS with no residual disease and with macroscopic residual disease, respectively. Survival was significantly better in patients with no RD following surgery, whichever initial management (PDS or NACT–IDS) (p < 0.01)
results reported by Ozols [34], Trimbos [35] and Nejtt [36]. A matter of debate in patients with advanced ovarian cancer (stage III–IV) was the possible delay to initiate chemotherapy following cytoreductive surgery especially in patients undergoing radical procedures. A recent meta-analysis by Mahner et al. [37] concluded a delayed chemotherapy was associated with early disease recurrence and significantly decreased OS following initial surgery in patients with complete resection. As so, inappropriate timing of chemotherapy could compromise the surgical effort to achieve no residual disease resulting in a double negative effect with high postoperative morbidity and shorten survival. Thus, it is imperative to select patients that will benefit from an upfront radical surgery and those eligible to NACT–IDS to attempt reducing postoperative morbidity. The use of nomograms could be promising in this purpose. These tools have been validated in other malignancies to predict at a patient level the probability of a certain event to occur. Shim et al. developed a model for predicting incomplete cytoreduction in advanced ovarian cancer with good performances [38]. Others focused on developing prediction models for immediate postoperative complications. Should they be validated, these nomograms could be used to help surgeons determine the most appropriate management for patients with advanced diseases. Finally, we cannot emphasize more the role of the surgeon’s experience and the institution to decide which management fits a certain patient best as it has been demonstrated before [39]. More studies are required to define better the indications of PDS and NACT–IDS in stage IV advanced ovarian cancer.

Conclusion

We demonstrated patients with stage IV ovarian cancer benefit from a cytoreductive surgery, with the most important prognostic factor being postoperative residual disease. Presence of distant metastases should not refrain surgeons from performing radical or ultra-radical procedures, whenever the patient is able to tolerate it. Extensive efforts should be done to minimize residual disease in these patients as their prognostic seems driven by the abdominal disease extension.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12967-020-02295-y.

Acknowledgements

Not applicable.

Authors’ contributions

Conceptualization: CT, BH, ED. Validation: CH, VL. Formal analysis: YD, CH, LO. Investigation: MB, SB, LO, PC, AB. Data curation: PC, AB, VL. Original draft: YD, CH, CT. Review: All authors. Visualization: SB, ED. Supervision: CT, BH, MB, ED All authors revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

The research protocol was approved by the Institutional Review Board (IRB) of the French College of Obstetrics and Gynecology (CEROG 2016-GYN-1003). As our study was non-interventional and retrospective, formal written consent from patients included was not necessary.

Consent for publication

Not applicable.

Competing interests

Prof C. Touboul occasionally serve as a consultant for Astra Zeneca, AB Medica, Conmed and TBWA-Adelphi. The remaining authors have nothing to disclose.

Author details

1. Department of Obstetrics and Gynecology, Centre Hospitalier Intercommunal, Faculté de médecine de Créteil UPEC-Paris XII, Créteil, France. 2. Department of Gynecology and Obstetrics, Intercommunal Hospital Centre of Poissy – Saint Germain – en – Laye, 78103 Poissy, France. 3. Department of Obstetrics and Gynecology, Centre hospitalier régional universitaire de Tours, hôpital Bicêtre, Tours, France. 4. Department of Gynecology and Obstetrics, Tenon University Hospital, Assistance Publique, Hôpitaux de Paris (AP-HP) des, Université Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), Paris, France. 5. Department of Obstetrics and Gynecology, Centre Hospitalier Régional Universitaire, Lille, France. 6. Department of Obstetrics and Gynecology, Jean–Verdier University Hospital, Assistance Publique, Hôpitaux de Paris (AP-HP) des, Paris, France. 7. CRCG: Eugène-Merquis, Department of Gynecology, CHU de Rennes, Université de Rennes 1, Rennes, France. 8. Service de Gynécologie Obstétrique, Hôpital Intercommunal de Créteil, 40 Avenue de Verdun, Créteil 94000, France.

Received: 7 October 2019 Accepted: 11 March 2020

Published online: 23 March 2020

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–92.
3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival value of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.
4. Vergote I, TropéCG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.
5. Chang S-J, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013;130(3):493–8.
6. Luycks M, Leblanc E, Filleton T, Monic P, Darai E, Classe J-M, et al. Maximal cytoreduction in patients with FIGO stage IIIIC to stage IV ovarian,
fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. Int J Gynecol Cancer. 2012;22(8):1337–43.

7. Pommel C, Dauplat J. Management of malignant epithelial tumors of the ovary. J Clin Oncol. 2004;14(15):277–84.

8. Ren Y, Jiang R, Yin S, You C, Liu D, Cheng X, et al. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIIC and IV ovarian cancer: an observational study. BMC Cancer. 2015;15:583.

9. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.

10. Chi DS, Zivanovic O, Levinson KL, Kolev V, Mottino D, et al. Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. PLoS ONE. 2012;7(7):e39415.

11. Keheo S, Hook J, Nankivel M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHOURUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.

12. Rauh-Hain JA, Melamed A, Wright A, Godley A, Clemen JT, Schorge JO, et al. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol. 2017;3(1):76–82.

13. Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Bonita DM, Horowitz NS, et al. Primary-debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012;19(3):959–65.

14. Curtin JP, Malik R, Venkataraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. JAMA Oncol. 2017;3(11):1199–1200.

15. Bristow RE, Montz FJ, Lagaasde LS, Leuchter RS, Karlan BY. Survival impact of interval debulking in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):278–87.

16. Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cilbwy A. Assessment of outcomes and morbidity following diaphragmatic peritoneectomy for women with ovarian carcinoma. Gynecol Oncol. 2008;109(2):303–7.

17. Stashwick C, Post MD, Arruda JS, Spillman MA, Heitz F, Traut A, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer. 2013;49(1):142–9.

18. Rauh-Hain JA, Nankivel M, Jayson GC, Kitchener H, Lopes T, et al. Improved progression-free and overall survival in advanced ovarian cancer: extending the boundaries. Ann Surg Oncol. 2017;24(12):3700–7.

19. Olszewska MM, Bader RN, McGill JA, Bowling LR, Olivier JM, Webster RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194–200.

20. Makar AP, Tropé CG, Tummers P, Denys H, Van Daele K. Advanced ovarian cancer: primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: primary debulking surgery and interval debulking surgery for advanced ovarian cancer. Ann Oncol. 2017;28(1):316–22.

21. Dabi G, Tanyel CU, Czernobilsky G, Pruett TL, Meurman C, et al. Peritoneal carcinomatosis index: a prognostic tool in advanced ovarian cancer. Gynecol Oncol. 2017;140(2):215–20.

22. Perri T, Ben-Baruch G, Kalfon S, Beiner ME, Helpman L, Hogen LB-D, et al. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction? Gynecol Oncol. 2017;131(1):27–31.

23. Clavien PA, Sanabria JR, Strausberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111(5):518–26.

24. Chang S-J, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining «optimal» residual disease. Gynecol Oncol. 2012;125(2):483–92.

25. Petrelli M, Zannoni GF, Tortorella L, Pedone Anchetta L, Salutari V, Encoli A, et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol. 2014;211(6):632.e1–8.

26. Makar AP, Tropé CG, Tummers P, Denys H, Van Daele K. Advanced ovarian cancer: primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: primary debulking surgery and interval debulking surgery for advanced ovarian cancer. Oncologist. 2016;21(6):745–54.

27. Rosenzweig S, de Gaetano E, Høgdall C. Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2016;26(2):316–22.

28. Eisenkop SM, Spitzer NW, Friedman RL, Lin WC-M, Pisani AL, Perticucci O. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90(2):390–6.

29. Ataseven I, Grimm C, Harter P, Heitz F, Traut A, Prader S, et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol. 2016;140(2):215–20.

30. Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2008;26(13):183–9.

31. Nasser S, Kryggiou M, Krell I, Hadjopoulos D, Bristow R, Fotopoulou C. A review of thoracic and mediastinal cytoreductive techniques in advanced ovarian cancer: extending the boundaries. Ann Surg Oncol. 2017;24(12):3700–7.

32. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194–200.

33. Olszewska MM, Bader RN, McGill JA, Bowling LR, Olivier JM, Webster RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194–200.

34. Reuss A, Prud'homme E, Eulenburg C, Staehle A, Wegscheider K, Reuss A, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst. 2003;95(2):113–25.

35. Reut J, Engelholm SA, Tuxen MK, Soerensen PG, Jensen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18(17):3084–92.

36. Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer. 2013;49(1):142–9.

37. Shim S-H, Lee SJ, Kim S-Q, Kim S-N, Kim D-Y, Lee JJ, et al. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients. Gynecol Oncol. 2015;136(1):30–6.

38. Querleu D, Ray-Coquard I, Classe JM, Aucouturier JS, Bonnet F, Bonnier P, et al. Quality indicators in ovarian cancer surgery: report from the French society of gynecologic oncology (Societe Francaise d'Oncologie Gynecologique, SFOG). Ann Oncol. 2013;24(11):2732–9.